Company
Headquarters: Long Beach, CA, United States
CEO: Mr. Charles A. Strongo BA, M.B.A., MBA
$1.3 Million
USD as of Jan. 1, 2024
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Nunzia Pharmaceutical Corporation operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute NUNZIA, a drug that treats autism, fragile X, ADHD, and PTSD. It offers its products through wholesalers, as well as through its website www.nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Corporation in February 2018. Nunzia Pharmaceutical Corporation was incorporated in 1986 and is based in Long Beach, California.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Nunzia Pharmaceutical Corp has the following listings and related stock indices.
Stock: OTC: NUNZ wb_incandescent